In a groundbreaking article panel during Phacilitate Advanced Therapy Week 2023, industry experts reveal the key factors driving commercialization success in the fast-evolving field of regenerative medicine.
The discussion emphasizes the pivotal role of early adoption and strategic partnerships in unlocking the potential for success in this cutting-edge industry. By recognizing the importance of staying ahead of the curve and embracing innovations, companies can position themselves as leaders in the regenerative medicine landscape.
Moreover, the power of collaborative partnerships is highlighted as a game-changer in driving commercialization efforts. By leveraging the expertise of multiple stakeholders, including researchers, clinicians and industry players, cell and gene therapy manufacturers can navigate complex challenges and accelerate the delivery of groundbreaking therapies to patients.
The insights provided by industry pioneers in the panel – Terumo’s Stuart Gibb, Ph.D., Scientific Strategy Lead at Terumo Blood and Cell Technologies; Nisha C. Durand, Ph.D., Principal Research Technologist at Mayo Clinic; and Matthew M. Hewitt, B.A. Ph.D., Executive Director, Scientific Services Cell and Gene Therapy at Charles River – shed light on how visionary organizations are thriving in regenerative medicine commercialization. By embracing a forward-thinking approach and forming strategic alliances, these early adopters are setting new standards for success in the industry.
